Obesity drug sales soar
![Obesity drug sales soar](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/f396f07211c5916076bdaf6d5eba5f19.jpg)
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Eli Lilly https://seekingalpha.com/news/4063037-eli-lilly-stock-gains-q4-beats-obesity-drugs?source=wsb_podcast:obesity_drug_sales_soar sales forecasts. (0:16) DuPont https://seekingalpha.com/news/4063007-duponts-stock-rises-on-dividend-hike-stock-buyback?source=wsb_podcast:obesity_drug_sales_soar and launches buyback. (1:37) NYCB's https://seekingalpha.com/news/4062935-nycbs-drastic-financial-moves-followed-tense-talks-with-occ-report?source=wsb_podcast:obesity_drug_sales_soar left before it announced shock results. (2:38) Show Notes https://seekingalpha.com/news/4062707-oppenheimers-buy-vs-sell-ideas-paired-by-each-smid-sector?source=wsb_podcast:obesity_drug_sales_soar https://seekingalpha.com/news/4063082-docusign-to-shrink-headcount-company-will-stay-public-after-failed-takeover-talks?source=wsb_podcast:obesity_drug_sales_soar Episode transcripts https://seekingalpha.com/wsb?source=wsb_podcast:obesity_drug_sales_soar Sign up...
show moreShow Notes
Oppenheimer's Buy vs. Sell ideas paired by each SMID sector
DocuSign to shrink headcount; company will stay public after failed takeover talks
Episode transcripts seekingalpha.com/wsb
Sign up for our daily newsletter here and for full access to analyst ratings, stock quant scores, dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions.
Information
Author | Seeking Alpha |
Website | seekingalpha.com |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company